What is the first‑line pharmacologic treatment for an adult with attention‑deficit/hyperactivity disorder (ADHD) who has no contraindications such as uncontrolled hypertension, significant cardiac disease, severe substance‑use disorder, or pregnancy?

First-Line Treatment for ADHD in Adults

Stimulant medications—specifically methylphenidate or amphetamine-based agents (e.g., lisdexamfetamine, mixed amphetamine salts)—are the first-line pharmacologic treatment for adults with ADHD who have no contraindications. These agents achieve response rates of 70–80% when properly titrated and produce the largest effect sizes (≈1.0) of any ADHD medication class, with therapeutic effects observable within days. 1, 2

Why Stimulants Are First-Line

• Amphetamine-based stimulants are preferred for adults based on comparative efficacy studies, with methylphenidate serving as an equally effective alternative. 1, 2
• Stimulants work rapidly—within days—allowing quick assessment of treatment response, unlike non-stimulants which require 2–12 weeks for full effect. 1, 2
• Approximately 40% of patients respond to both stimulant classes (methylphenidate and amphetamine), while another 40% respond to only one class, supporting trials of both before moving to non-stimulants. 1, 2
• The evidence base is robust: over 161 randomized controlled trials demonstrate consistent efficacy across the adult lifespan. 1

Specific Stimulant Options and Dosing

Amphetamine-Based Agents

• Lisdexamfetamine (Vyvanse): Start 20–30 mg once daily in the morning, titrate by 10–20 mg weekly up to 70 mg maximum. 1, 2, 3
• Mixed amphetamine salts (Adderall XR): Start 10 mg once daily in the morning, titrate by 5 mg weekly up to 50 mg maximum (though doses up to 65 mg may be used when lower doses are insufficient and well-tolerated). 1, 2

Methylphenidate Formulations

• Extended-release methylphenidate (Concerta): Start 18 mg once daily in the morning, increase by 18 mg weekly up to 54–72 mg maximum. 1, 2
• Immediate-release methylphenidate: 5–20 mg three times daily, with maximum daily dose of 60 mg. 1, 2
• Long-acting formulations are strongly preferred due to better adherence, more consistent symptom control, reduced rebound effects, and lower diversion potential. 1, 2

Baseline Assessment Before Initiating Stimulants

• Measure blood pressure and pulse—stimulants typically raise systolic/diastolic pressure by 3–5 mm Hg and heart rate by 5–10 bpm. 1, 2
• Obtain detailed cardiac history: screen for sudden cardiac death in family members <50 years, syncope, chest pain, palpitations, Wolff-Parkinson-White syndrome, hypertrophic cardiomyopathy, Long QT syndrome. 1
• Screen for substance-use disorders, as active stimulant abuse is an absolute contraindication. 1, 2
• Document all prior ADHD treatments, doses, duration, response, and side effects. 1

Monitoring During Treatment

• Titration phase (first 4–6 weeks): Check blood pressure and pulse weekly, obtain ADHD symptom ratings weekly, assess sleep quality and appetite changes. 1, 2
• Maintenance phase: Monitor blood pressure and pulse quarterly in adults; continue tracking sleep, appetite, and functional improvement across work, home, and social settings. 1, 2

When to Consider Non-Stimulants Instead

Non-stimulant medications are reserved as second-line options after failure of ≥2 stimulant trials, intolerable stimulant side effects, or when specific contraindications exist. 1, 2, 4

Atomoxetine (Strattera)

• Target dose: 60–100 mg daily (maximum 1.4 mg/kg/day or 100 mg, whichever is lower). 1, 2, 4
• Requires 6–12 weeks for full therapeutic effect (median 3.7 weeks), with effect size ≈0.7 compared to stimulants. 1, 2, 4
• Provides 24-hour coverage, has no abuse potential, making it useful when substance-misuse risk exists. 1, 2, 4
• FDA black-box warning for suicidal ideation requires baseline and regular screening. 1, 2

Alpha-2 Adrenergic Agonists

• Extended-release guanfacine (Intuniv): Start 1 mg nightly, titrate to 0.05–0.12 mg/kg/day (maximum 7 mg). 1, 2
• Extended-release clonidine (Kapvay): Similar dosing to guanfacine. 1, 2
• Both have effect sizes ≈0.7, require 2–4 weeks for full effect, and are particularly useful for comorbid sleep disturbances, anxiety, or tics. 1, 2
• Evening dosing is preferred due to sedative properties. 1, 2

Other Non-Stimulants

• Bupropion: Modest ADHD activity with effect size ≈0.7; considered second-line, particularly useful when depression is comorbid. 1, 2, 4
• Viloxazine extended-release (Qelbree): Emerging option with favorable tolerability in pediatric trials, though adult data remain limited. 1, 4

Absolute Contraindications to Stimulants

• Concurrent MAOI use or within 14 days of MAOI discontinuation (risk of hypertensive crisis). 1
• Active psychotic disorder or mania. 1
• Symptomatic cardiovascular disease or uncontrolled hypertension. 1, 2
• Prior hypersensitivity to stimulants. 1
• Active stimulant use disorder (though long-acting formulations with lower abuse potential may be considered in controlled settings). 1, 2

Common Pitfalls to Avoid

• Do not under-dose stimulants out of fear of side effects—systematic titration protocols enable 70% of patients to achieve optimal response. 1, 2
• Do not switch stimulant classes prematurely—ensure the first agent has been titrated to maximum tolerated dose before labeling it as failed. 1, 2
• Do not delay ADHD treatment due to comorbid anxiety or mild mood symptoms—stimulants do not exacerbate anxiety and may yield higher response rates in anxious subgroups; if mood/anxiety symptoms persist after ADHD improvement, add an SSRI to the stimulant regimen. 1, 2
• Do not assume immediate-release formulations are equivalent to long-acting—extended-release products provide superior adherence, consistent coverage, and lower abuse potential. 1, 2

Multimodal Treatment Approach

• Combine pharmacotherapy with evidence-based psychosocial interventions—Cognitive Behavioral Therapy (CBT) specifically developed for ADHD is the most extensively studied and effective psychotherapy, with increased effectiveness when combined with medication. 1, 2
• Mindfulness-based interventions (MBCT, MBSR) help most profoundly with inattention symptoms, emotion regulation, executive function, and quality of life. 1, 2